Sign up to access historical data
Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$590M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
AmgenAMGN |
-$108M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Watton Corey Michael | Mar 28, 2025 | Buy | 300 | $7.8384 | $2,400 |
| Bode John B | Mar 19, 2025 | Buy | 10,000 | $7.9624 | $80,000 |
| McFarlane Neil F. | Feb 14, 2025 | Sell | 30,544 | $8.0527 | $250,000 |
| Schafer Joshua | Feb 13, 2025 | Sell | 10,500 | $7.8597 | $83,000 |
| Clifton R. LaDuane | Feb 13, 2025 | Sell | 11,000 | $7.861 | $86,000 |
| McFarlane Neil F. | Feb 13, 2025 | Sell | 61,273 | $7.8571 | $480,000 |
| Sangiovanni Timothy J. | Feb 13, 2025 | Sell | 3,000 | $7.8626 | $24,000 |
| Watton Corey Michael | Oct 11, 2024 | Buy | 500 | $7.9153 | $4,000 |
| Clifton R. LaDuane | Jul 17, 2024 | Buy | 2,000 | $6.77 | $14,000 |
| Anderson Thomas | Jul 16, 2024 | Buy | 10,000 | $6.8065 | $68,000 |
| Bode John B | Jul 12, 2024 | Buy | 10,000 | $5.8661 | $59,000 |
| Anderson Thomas | Sep 6, 2023 | Buy | 10,000 | $4.8764 | $49,000 |
| Clifton R. LaDuane | Sep 6, 2023 | Buy | 1,000 | $4.9591 | $5,000 |
| Bode John B | Sep 5, 2023 | Buy | 10,000 | $5.1333 | $51,000 |
| Schafer Joshua | Sep 5, 2023 | Buy | 500 | $5.129 | $2,600 |
What's the latest insider transaction for Zevra Therapeutics?
The most recent insider transaction for Zevra Therapeutics was conducted by Watton Corey Michael, who sold 300 shares on March 28, 2025 at a price of $7.84 per share.
Which insider bought the most ZVRA stock over the last two years?
Bode John B has bought the most ZVRA stock in the last 2 years, with a total value of $190,000.
Which insider has sold the most ZVRA stock over the last two years?
McFarlane Neil F. has sold the most ZVRA stock in the last 2 years, with a total value of $730,000.
What is the total value of insider transactions for Zevra Therapeutics (ZVRA) in the last 2 years?
The total value of insider transactions for Zevra Therapeutics in the last 2 years is negative, amounting to -$590,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Zevra Therapeutics' market confidence?
Over the last 2 years, insider transactions for Zevra Therapeutics have predominantly involved purchasing shares, indicating a strong confidence among insiders in the company's future prospects. This trend of more purchases than sales could be a positive signal to potential investors about the insiders' view on the company's valuation and growth potential.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
